



This is a repository copy of *Tumour necrosis factor- α antagonists as therapies for vitiligo*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/90664/>

Version: Accepted Version

Article:

Kemp, E.H. (2015) Tumour necrosis factor- α antagonists as therapies for vitiligo. *British Journal of Dermatology*, 173 (3). 635 . ISSN 0007-0963

<https://doi.org/10.1111/bjd.14057>

This is the peer reviewed version of the following article: Kemp, E.H. (2015) Tumour necrosis factor- α antagonists as therapies for vitiligo. *British Journal of Dermatology*, 173 (3). 635., which has been published in final form at <http://dx.doi.org/10.1111/bjd.1405>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Commentary – Tumor necrosis factor- α antagonists as therapies for vitiligo

Vitiligo is a common cutaneous disease resulting from the loss of epidermal melanocytes.¹ Although the aetiology and pathogenesis of vitiligo are not completely understood, cytotoxic T cell responses against melanocytes clearly play a prominent role in the pathophysiology of the disease.² In addition, an imbalance of cytokines within vitiligo-affected skin has been implicated in the destruction of melanocytes.³ For example, epidermal levels of the proinflammatory cytokine tumor necrosis factor (TNF)- α are increased in vitiligo skin and, indeed, correlate directly with on-going depigmentation.⁴ TNF- α can activate cytotoxic T cells in the skin,⁵ inhibit the proliferation of melanocytes⁶ and also cause melanocytes to apoptose.⁷ Such findings have prompted the investigation of TNF- α inhibitors as agents that may prevent melanocyte loss and also initiate repigmentation in vitiligo patients.

In this issue of the *BJD*, Webb *et al*⁸ have reviewed the literature pertaining to the use of anti-TNF- α mediators such as infliximab, etanercept and adalimumab as therapeutic tools for vitiligo. Their findings revealed that blocking the action of TNF- α effectively stopped the progression of vitiligo and initiated repigmentation in almost all patients with active disease, presumably at least in part due to the stemming of cytotoxic T cell-mediated destruction of melanocytes. Importantly, the researchers noted that the arrest of melanocyte loss was as valid in assessing the success of treatment as observing actual repigmentation, concluding that future clinical trials will need to effectively evaluate both parameters.

Interestingly, the literature reported a small proportion of non-vitiligo patients who were receiving treatment with TNF- α antagonists adalimumab and infliximab for other autoimmune diseases and who developed depigmentation. The authors of the review suggest that this phenomenon results from a decrease in the production and activation of regulatory T cells (Tregs) which are normally stimulated by TNF- α ⁹ and act to suppress cytotoxic T cell activity.¹⁰ If Treg cell numbers are reduced in the skin, then T lymphocytes cytotoxic to melanocytes may exert their effects leading to pigment cell loss. Simultaneous treatment to recruit Tregs to the epidermis may overcome this adversity in susceptible individuals.

Overall, inhibitors of TNF- α were found to be beneficial for patients with progressing vitiligo. However, the possibility that vitiligo can be initiated by TNF- α antagonists may thwart their wider use as treatments for the disease.

Conflicts of interest

None declared.

DR. E. HELEN KEMP

Department of Human Metabolism

University of Sheffield

Sheffield S10 2RX

U.K.

Email – e.h.kemp@sheffield.ac.uk

References

- 1 Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. *J Am Acad Dermatol* 2011; **65**:473-91.
- 2 van den Boorn JG, Konijnenberg D, DelleMijn TA *et al.* Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. *J Invest Dermatol* 2009; **129**:2220-32.
- 3 Moretti S, Spallanzani A, Amato L *et al.* New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. *Pigment Cell Res* 2002; **15**: 87–92.
- 4 Kim NH, Torchia D, Rouhani P *et al.* Tumor necrosis factor- α in vitiligo: direct correlation between tissue levels and clinical parameters. *Cutan Ocul Toxicol* 2011; **30**: 225-7.
- 5 Ranges GE, Figari IS, Espevik T *et al.* Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α . *J Exp Med* 1987; **166**: 191-8.
- 6 Swope VB, Abdel-Malek Z, Kassem LM *et al.* Interleukins 1 α and 6 and tumor necrosis factor α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. *J Invest Dermatol* 1991; **96**: 180–5.
- 7 Kim NH, Jeon S, Lee HJ *et al.* Impaired PI3K/Akt activation-mediated NF-kappa B inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. *J Invest Dermatol* 2007; **127**: 2612-7.

- 8 Webb KC, Tung R, Winterfield LS *et al.* TNF- α inhibition to stabilize disease and set the stage for repigmentation in progressive vitiligo. *Br J Dermatol* 2015; in press.
- 9 Biton J, Boissier MC, Bessis N. TNF-alpha: activator or inhibitor of regulatory T cells? *Joint Bone Spine* 2012; **79**: 119-23.
- 10 Chatterjee S, Eby JM, Al-Khami AA *et al.* A quantitative increase in regulatory T cells controls development of vitiligo. *J Invest Dermatol* 2013; **135**: 1285-94.